The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > COMMENTARY
COMMENTARY
- Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
May 10, 2022
- SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
April 22, 2022
- Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
- Drug Makers Forced to Make Tough Decisions on AG Strategies: Licensing Profits or Losses on Early G1 Cuts?
April 8, 2022
- Drug Makers Guard against Price Adjustment Rate, Off-Year Revision Debates: Jiho Poll
March 16, 2022
- Drug Makers in Japan Increasingly Tested for Product Prowess, Rather than Marketing Ability
February 25, 2022
- Will New Economic Security Bill Contribute to Ensuring Stable Drug Supplies?
February 16, 2022
- JPMA Chief’s Comments to Endorse Coverage Review Send Ripples through Industry
February 3, 2022
- Significance and Challenges around Proposed Emergency Approval Scheme, Eyes on Diet Debate
January 17, 2022
- Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
December 20, 2021
- Public-Private Collaboration Needed to Refine SaMD Regulatory System
November 26, 2021
- MOF, MHLW Push Conflicting Narratives on Drug Cost Control; Macroeconomic Indexing Is a Major Focus Too
November 16, 2021
- SGLT2 Inhibitors, Entresto Could Change Paradigm of Treatment of Heart Failure: JHFS Annual Confab
October 26, 2021
- LDP’s Pharma Study Group at Critical Juncture as Kishida Vows to Rectify Power Balance, Kingpins Retire
October 19, 2021
- Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
October 15, 2021
- Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
October 13, 2021
- 5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
September 29, 2021
- CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
August 3, 2021
- Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
- Updated Heart Failure Guidelines Position Entresto, SGLT2 Inhibitors as New Treatment Strategy Options
June 22, 2021
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…